Clinical study on pre-transplant conditioning regimens in acute myeloid leukemia in children
Résumé de l'étude
The SCRIPT-AML study is an international clinical study investigating conditioning chemotherapy prior to hematopoietic cell transplantation (HCT) in children, adolescents, and young adults with acute myeloid leukemia (AML). The main objective of the SCRIPT-AML study is to compare the tolerance and efficacy of two different conditioning regimens used in the treatment of AML in children and adolescents. This study consists of different parts: an interventional part that includes randomization (i.e., a random allocation of participants into different groups) and an observational part.
(BASEC)
Intervention étudiée
Based on predefined criteria, it will be decided whether the patient can participate in the randomization or the observational arm of the SCRIPT-AML project.
Randomization:
As part of the randomization, the patient will receive one of the following chemotherapy combinations during the conditioning phase prior to HCT:
• BuCyMel: busulfan, cyclophosphamide, melphalan
• CloFluBu: clofarabine, fludarabine, busulfan
Patients will be randomly assigned (randomization) to the two groups. Both combinations have already been successfully used for pre-HCT conditioning in cases of acute myeloid leukemia. The controlled comparison of BuCyMel with CloFluBu in this study will allow for the assessment of whether one of the conditioning protocols is more effective or associated with fewer side effects than the other or whether, conversely, both protocols are equivalent.
Observational arm: Unlike the randomization, in the observational arm, the treating physician will decide on the chemotherapy combination administered during the pre-HCT conditioning phase.
(BASEC)
Maladie en cours d'investigation
Acute myeloid leukemia
(BASEC)
- Children ≤ 18 years at the time of diagnosis and ≤ 21 years at the time of HCT, diagnosed with - AML and having an indication for HCT according to the protocol, with - an acceptable HLA-compatible stem cell donor and in hematological remission at the time of HCT. (BASEC)
Critères d'exclusion
- Secondary AML or primary refractory disease requiring "off-protocol" treatment - Excessive risk of toxicity (such as Down syndrome, Fanconi anemia) - Previous stem cell transplantation (BASEC)
Lieu de l’étude
Bâle, Genève, Zurich
(BASEC)
Sponsor
Västra Götaland Regionen (Sweden) Schweizerische Pädiatrische Onkologie Gruppe
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Prof. Dr. med. Marc Ansari
+41 22 372 47 31
marc.ansari@clutterhug.chHUG Hôpitaux Universitaires Genève
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Commission cantonale d'éthique de Genève
(BASEC)
Date d'approbation du comité d'éthique
24.06.2024
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
Studying Conditioning Regimen In Pediatric Transplantation – AML (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible